SYNGENE — Syngene International Share Price
- IN₹360.09bn
- IN₹354.67bn
- IN₹34.89bn
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 59.54 | ||
PEG Ratio (f) | 4.8 | ||
EPS Growth (f) | 14.15% | ||
Dividend Yield (f) | 0.18% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 8.46 | ||
Price to Tang. Book | 8.52 | ||
Price to Free Cashflow | 67.77 | ||
Price to Sales | 10.38 | ||
EV to EBITDA | 34.21 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 12.1% | ||
Return on Equity | 12.5% | ||
Operating Margin | 17.47% |
Financial Summary
Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | IN₹m | 20,119 | 21,843 | 26,042 | 31,929 | 34,886 | 38,078.1 | 44,431.55 | 13.83% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +6.75 | +4.81 | +11.71 | +11.53 | +11.28 | +3.88 | +23.87 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development (R&D), current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. Its business divisions include discovery services, R&D centers, development services, and manufacturing services. It serves the pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals. It operates multi-modal biologics manufacturing facility.
Directors
- Kiran Shaw CHM (68)
- Jonathan Hunt CEO
- M. Chinappa CFO
- Manoj Nerurkar COO
- Priyadarshini Mahapatra CCO
- Sebi Chacko OTH
- Anita Chugh OTH
- Dhananjay Patankar OTH
- Purushottam Singnurkar OTH
- Jegadeesh Thampi OTH
- Subhash Thuluva OTH
- Catherine Rosenberg NED
- Carl Decicco IND
- Sharmila Karve IND
- Vinita Bali NID (65)
- Paul Blackburn NID (66)
- Daniel Bradbury NID (60)
- Vijay Kuchroo NID (66)
- Bala Manian NID (75)
- Kush Parmar NID (40)
- John Russell Walls NID (71)
- Last Annual
- March 31st, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- November 18th, 1993
- Public Since
- August 11th, 2015
- No. of Shareholders
- 118,975
- No. of Employees
- 6,510
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 400,808,420
- Address
- Syngene International Ltd, BANGALORE, 560099
- Web
- https://www.syngeneintl.com/
- Phone
- +91 8068918000
- Contact
- Krishnan G
- Auditors
- BSR & Co. LLP
Upcoming Events for SYNGENE
Q3 2025 Syngene International Ltd Earnings Release
Similar to SYNGENE
Biocon
National Stock Exchange of India
Indo US Bio-Tech
National Stock Exchange of India
Suven Life Sciences
National Stock Exchange of India
Take Solutions
National Stock Exchange of India
Vimta Labs
National Stock Exchange of India
FAQ
As of Today at 23:33 UTC, shares in Syngene International are trading at IN₹898.40. This share price information is delayed by 15 minutes.
Shares in Syngene International last closed at IN₹898.40 and the price had moved by +11.72% over the past 365 days. In terms of relative price strength the Syngene International share price has underperformed the S&P BSE 100 Index by -18.11% over the past year.
The overall consensus recommendation for Syngene International is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Syngene International dividend yield is 0.14% based on the trailing twelve month period.
Last year, Syngene International paid a total dividend of IN₹1.25, and it currently has a trailing dividend yield of 0.14%. We do not have any data on when Syngene International is to next pay dividends.
We do not have data on when Syngene International is to next pay dividends. The historic dividend yield on Syngene International shares is currently 0.14%.
To buy shares in Syngene International you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹898.40, shares in Syngene International had a market capitalisation of IN₹360.09bn.
Here are the trading details for Syngene International:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: SYNGENE
Based on an overall assessment of its quality, value and momentum Syngene International is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Syngene International is IN₹759.50. That is 15.46% below the last closing price of IN₹898.40.
Analysts covering Syngene International currently have a consensus Earnings Per Share (EPS) forecast of IN₹13.47 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Syngene International. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +6.95%.
As of the last closing price of IN₹898.40, shares in Syngene International were trading +20.65% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Syngene International PE ratio based on its reported earnings over the past 12 months is 59.54. The shares last closed at IN₹898.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Syngene International's management team is headed by:
- Kiran Shaw - CHM
- Jonathan Hunt - CEO
- M. Chinappa - CFO
- Manoj Nerurkar - COO
- Priyadarshini Mahapatra - CCO
- Sebi Chacko - OTH
- Anita Chugh - OTH
- Dhananjay Patankar - OTH
- Purushottam Singnurkar - OTH
- Jegadeesh Thampi - OTH
- Subhash Thuluva - OTH
- Catherine Rosenberg - NED
- Carl Decicco - IND
- Sharmila Karve - IND
- Vinita Bali - NID
- Paul Blackburn - NID
- Daniel Bradbury - NID
- Vijay Kuchroo - NID
- Bala Manian - NID
- Kush Parmar - NID
- John Russell Walls - NID